Noor Atiqah Fakharuzi1*, Kamal Shaik Fakiruddin1, Wan Sakeenah Wan Nazri1, Yuslina Mat Yusoff2, Sujatha Suthandiram2, Adiratna Mat Ripen2, Lim Moon Nian1
1. Good Manufacturing Practice Laboratory, Biomedical Research Core Facility, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia
2. Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia
*Corresponding author: Noor Atiqah Fakharuzi.
ABSTRACT
INTRODUCTION: The manufacturing of Cell and Gene Therapy Products (CGTPs), such as Mesenchymal Stem Cells (MSCs) for clinical application, requires a robust quality system to ensure consistent product quality, safety, and efficacy. Equipment qualification is a critical component of GMP compliance, as equipment performance directly influences the cell viability, identity, and function. Thus, applying a Quality by Design (QbD) approach enables early identification and control of critical process variables that directly influence product quality.
OBJECTIVE(S): This study aimed to implement a QbD framework and risk assessment for qualifying GMP equipment used in the large-scale manufacturing of MSCs. The objective was to correlate Critical Process Parameters (CPPs) with relevant Critical Quality Attributes (CQAs) across distinct stages of the MSC production process.
MATERIALS & METHODS: The MSC manufacturing workflow comprises four main stages: umbilical cord collection, master cell bank generation, working cell bank expansion, and final product filling. Critical equipment was evaluated as part of the qualification process. A risk rating matrix was used to classify equipment based on its potential impact on functional (fCQA), manufacturing (mCQA), and in-process CQAs (iCQA). Qualification was conducted according to the GMP equipment validation protocol recommended by PIC/S guidelines, which includes Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ).
RESULTS: The QbD-driven, risk-based qualification process ensures consistent equipment performance supporting high-quality MSC expansion. Equipment affecting high-impact CQAs, such as sterility, underwent rigorous PQ validation. CO2 incubators were validated for temperature and CO2 stability (impacting iCQA), biosafety cabinets for aseptic handling (impacting mCQA and fCQA), while refrigerators and freezers were validated for storage and freezing integrity (affecting mCQA).
CONCLUSION: Integrating QbD with risk-based equipment qualification enhances GMP compliance, supports scalable MSC manufacturing, and ensures readiness for future CGTPs such as CAR-T products within a controlled and validated environment.
KEYWORDS: Quality by Design, GMP, MSC, Risk Assessment, Equipment Qualification


